Business · 26/02/2026Updated: 10/16/2026 · 1 min read
FDA Determines Regulatory Review Period for ORLYNVAH Patent Extension
Summary
The FDA has determined the regulatory review period for ORLYNVAH, a human drug product, and is publishing this notice as required by law, following a submission to the USPTO for patent extension.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →